News

Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer

Deal value of up to US$525 million Novo Holdings co-led…

eTheRNA Announces Relocation and Expansion of R&D Facility

GENT, BELGIUM, April 5, 2022 – eTheRNA immunotherapies NV (“eTheRNA”),…

Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models

Findings published in the peer-reviewed journal ACS Chemical…

Novo Holdings’ Principal Investments Provides Update on a Record Year

Deployed close to EUR 1.9 billion of equity* Expanded portfolio…

Bionical Emas: Ian Fraser appointed as Executive Vice President, Clinical Development.

Bionical Emas, a global Contract Research Organisation (CRO)…

Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic

BioCity, Scotland, 30th March 2022  £1 million grant will…

Novo Holdings and HealthQuad invest in Qure.ai

The funding will accelerate the AI-driven healthcare company’s…

Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth

• Started clinical trial with lead candidate RJx-01 for treating…

eTheRNA Manufacturing Announces New LNP Formulation Development and Production Service

NIEL, BELGIUM, March 29, 2022, eTheRNA Manufacturing, a specialist…

EXACT Therapeutics Announces Appointment of Dr Per Walday as Chief Executive Officer

OSLO/LONDON, 28 March 2022: EXACT Therapeutics AS (“EXACT-Tx”,…

DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product

Turku, Finland – 28 March 2022: – DelSiTech Ltd, the leading…

Gadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences

GDT002 shown to have a potent anti-tumor activity across a…

Novo Holdings reports Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020

Copenhagen, Denmark – Novo Holdings realised Total Income…

Futura Announces Collaboration with Menarini Korea to Commercialise MED3000 in South Korea

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a…

Biocomposites signs agreement with Zimmer Biomet to distribute new genex Bone Graft Substitute

genex Bone Graft Substitute upgraded with a new closed-mixing…

Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals

Precirix NV, a clinical-stage biotechnology company developing…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

Get in touch

© Optimum Strategic Communications.